Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02752789 · ClinicalTrials.gov registry record

Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function

A clinical trial of Pediatric Heart Transplantation and Pediatric Heart Transplant Recipients, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
407
Enrollment target
9
Study locations

NCT02752789 is a study of Pediatric Heart Transplantation and Pediatric Heart Transplant Recipients that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 407 participants. The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02752789, a study of Pediatric Heart Transplantation and Pediatric Heart Transplant Recipients, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
407 participants
Enrollment target
9
Study locations

Study Summary

This is a multi-center, prospective, single cohort, observational study of pediatric heart transplant recipients designed to determine the impact of preformed versus de novo human leukocyte antigen (HLA) donor-specific antibodies (DSA), and antibodies to the self-antigens cardiac myosin and vimentin, on chronic allograft function. In addition, the investigators will explore mechanisms of action and predictors of DSA, rejection and altered pathophysiology.

Study Locations (9)

New York

  • Columbia University Medical Center - New York
  • Children's Hospital at Montefiore - New York

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Children's Hospital of Pittsburgh - Pittsburgh

Georgia

  • Emory University School of Medicine - Atlanta

Massachusetts

  • Children's Hospital Boston - Boston

Missouri

  • St. Louis Children's Hospital - St Louis

Tennessee

  • Monroe Carell Jr. Children's Hospital - Nashville

Other

  • Hospital for Sick Children - Toronto

Trial Details

FieldValue
Enrollment Target 407 participants
Start Date 2014-07-15
Est. Completion 2019-11-01

What the Registry Record Tells You About NCT02752789

The ClinicalTrials.gov registry entry for NCT02752789 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pediatric Heart Transplantation appearing as the primary indexed condition, and to 0 interventions.

NCT02752789 reports 9 study locations spanning 7 distinct geographic areas - top geographies include New York, Pennsylvania, Georgia.

Frequently Asked Questions

What is clinical trial NCT02752789 about?

NCT02752789 is a clinical study titled "Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function". This is a multi-center, prospective, single cohort, observational study of pediatric heart transplant recipients designed to determine the impact of preformed versus de novo human leukocyte antigen (HLA) donor-specific antibodies (DSA), and antibodies to the self-antigens cardiac myosin and vimentin...

What is the current status of trial NCT02752789?

This trial is currently completed. The enrollment target is 407 participants. The study started on 2014-07-15. Estimated completion is 2019-11-01.

What conditions does trial NCT02752789 study?

This clinical trial studies the following conditions: Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients.

Who is sponsoring clinical trial NCT02752789?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02752789 being conducted?

This trial has 9 study locations across Georgia, Massachusetts, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.